Reproducibility and clinical and concurrent validity of the MSF-4: A four-item male sexual function questionnaire for patients with benign prostatic hyperplasia

Value in Health

Volumn 4, Issue 4, 2001, Pages 335-343

  Marquis, P ^a   Marrel, A ^a  

^a MAPI VALUES   (United States)

Author keywords

5 reductase inhibitor; Benign prostatic hyperplasia; Male sexual function; MSF 4; Permixon; Questionnaire; Serenoa repens extract

Indexed keywords

ALFUZOSIN; FINASTERIDE; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

ADULT; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SCORING SYSTEM; SEXUAL FUNCTION; SYMPTOMATOLOGY;

EID: 0034869752     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2001.44021.x     Document Type: Article

References (28)

1. Benign prostatic hyperplasia (the aging prostate)
2. Prostate and sexuality: An overview
3. Effects of the 5-alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: A prospective clinical study
4. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia
5. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia
6. Tamsulosin 0. 4 mg once daily: Effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
7. Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: A population-based study
8. Relative importance of sexuality and quality of life in patients with prostatic symptoms
9. Schulman CCBPH and sexuality
10. A comparison of patient and partner responses to a brief sexual function questionnaire
11. A brief male sexual function inventory for urology
12. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction
13. Cross-sectional analysis
14. Assessing reliability and validity of measurement in clinical trials
15. Begnign prostatic hyperplasia and erectile dysfunction: A review
16. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation
17. Measuring the quality of life of patients with benign prostatic hyperplasia
18. A comparison of quality of life with patient reported symptoms and objective findings in men with Benign Prostatic Hyperplasia
19. Symptom status and quality of life following prostatectomy
20. Social functioning: Sexual problems measures
21. Construction et validation d'une échelle de qualité de vie liée à l'état de santé, spécifique de l'hypertrophie bénigne de la prostate et comportant une échelle d'évaluation de la sexualité
22. Long-term quality of life in patients with benign prostatic hypertrophy: Preliminary results of a cohort survey of 7.093 patients treated with an alpha-1-adrenergic blocker
23. Validation of a new quality of life questionnaire for Benign Prostatic Hyperplasia
24. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSSI) system for use in Benign prostatic hyperplasia
25. Effects of Finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia
26. Quality-of-life assessment in patients after laser prostatectomy